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Introduction
Analysis of cerebrospinal £uid (CSF) may be useful in the investigation of a number of disorders including infections (bacterial, mycobacterial, viral, fungal or protozoan), Guillain--Barre syndrome, demyelinating diseases, vasculitis, sarcoidosis and some inherited metabolic disorders. Measurement of immunoglobulin (Ig) titres for speci¢c diseases (e.g. syphilis and Lyme disease) may also be helpful. Possibly the most critical analysis is in the diagnosis of subarachnoid haemorrhage (SAH). Missing this diagnosis may have serious consequences for the patient.
CSF is commonly analysed for glucose and protein and less widely for other analytes such as haem pigments, lactate, glycine and oligoclonal bands. There is no clear guidance as to the preferred methods, or indeed the reference ranges, for some of these parameters even though there is information in the literature. There is clear guidance for the measurement of haem pigments 1 produced by the UK National External Quality Assessment Service (NEQAS) for Immunochemistry Working Group.
The UK NEQAS Specialist Advisory Group for EQA of CSF Proteins and Biochemistry decided to audit the provision for the investigation of CSF by hospital laboratories in the UK by means of a questionnaire.
Materials and methods
In the autumn of 2004 approximately 200 questionnaires (see Appendix) were sent out electronically via Association for Clinical Biochemistry regional audit committees to all laboratories who were known to those committees. These were returned as email attachments or as hard copy over a period of months, the last arriving in February 2005. Replies were received from Northern Ireland, Scotland, Wales and England. Most laboratories were identi¢able in some way despite the replies being anonymous.
The questionnaire asked about the population served, where the CSF was analysed (in biochemistry or microbiology or sent to another hospital laboratory), what parameters were measured, by what methods and what reference ranges used. There were questions about the provision of computed tomography (CT) or magnetic resonance imaging (MRI) scanners, if there were neurology or neurosurgical beds and detailed questions about the measurement of haem pigments in CSF because we were particularly interested in how patients with possible SAH were investigated.
Results
Eighty-four questionnaires were returned, 42 via email and 42 by post. Not all questions were answered in every case.
Most hospitals had access to CT or MRI scanning available 24 h a day. About half the hospitals had neurology beds and 18 hospitals neurosurgical beds. Populations served varied from 25,000 to 2.5 million with an average of 453,000.
Nearly all the laboratories used the UK NEQAS scheme. Of the 84 responses 72 participated in the NEQAS CSF scheme for protein, 74 for glucose, 53 for spectrophotometry, 22 for lactate and six for oligoclonal bands. Some laboratories relied on urine or serum schemes for protein, glucose and lactate. Three laboratories used ERNDIM (European Research Network for evaluation and improvement of screening, Diagnosis and treatment of Inherited disorders of Metabolism) schemes for amino acids.
Protein was measured almost exclusively in biochemistry laboratories (80 out of 84 responses, protein was measured in microbiology in two hospitals, neuroimmunology in one hospital and one did not o¡er CSF protein measurement), pyrogallol red was the most popular method (51% of those that stated their method) followed by benzethonium chloride (30%), there were 8% using Vitros technology, 3% biuret and one laboratory used Folin-Ciocalteu. These percentages for protein methods are similar to those found in the UK NEQAS for CSF Proteins and Biochemistry.
The most common reference range for protein was 0.15--0.45 g/L in adults, and most quoted ranges that fell somewhere between 0 and 0.45 g/L but three laboratories used 0.6 g/L and three 0.7, 0.8 and 1.0 g/L respectively as their upper limit. Many laboratories also quoted age-dependent paediatric ranges but none used age-dependent adult ranges. Age-related values do exist extending from pre-term to 77 years. 2 Glucose was also measured almost exclusively in biochemistry departments; hexokinase was the most popular method (56%), followed by glucose oxidase (33%) with 8% using Vitros analysers. The most popular reference range was 60% of serum concentration or 2.5--4.5 mmol/L but many other ranges were quoted spanning values from 50% up to 80% of serum concentration and from a lower limit of 2.0 mmol/L to an upper limit of 6.5 mmol/L.
Twenty-¢ve laboratories (all biochemistry) out of the 84 replies measured lactate in the CSF (30%). This compares with the 60% of participants in the UK NEQAS for CSF Protein and Biochemistry who measure lactate. There were a variety of methods used, some just stating, 'lactate oxidase' or 'lactate oxidase electrode'. Two laboratories used lactate electrodes on blood gas analysers. Nearly half the laboratories measuring lactate did not quote a reference range on their questionnaire. Quoted ranges varied from 0.8 to 3.1mmol/L with four laboratories using 1.2--2.1mmol/L. One laboratory gave higher values for neonates and children.
Five laboratories said they performed oligoclonal band analysis and also measured IgG and albumin in CSF. Details of these methods were not given. Other tests performed by a few laboratories included measuring amino acids, tau protein (asialylated transferrin) and angiotensin converting enzyme.
Fifty-six biochemistry laboratories used scanning spectrophotometry to detect haem pigments and bilirubin. Twenty-two hospitals sent their samples elsewhere for scanning. Six hospitals did not o¡er this service and together served a population of over two million. One of these hospitals was planning to introduce a service within three months of ¢lling in the questionnaire.
Twenty-¢ve laboratories visually inspected the CSF but in only two of these did the result of the inspection in£uence whether to continue spectroscopy ('no point in scanning obvious yellow samples' and 'depends on the CSF results, clinical picture and the demands of the clinician').
Most laboratories had a standard operating procedure (SOP) for collection of CSF. Forty-six out of 73 laboratories asked for four separate samples, most specifying a £uoride tube for glucose analysis and plain tubes for other tests. The last sample collected was used for spectrometry by most laboratories.
Seventy laboratories would accept samples received unprotected from the light. Forty would add a comment and seven laboratories would not accept them. Fortyseven laboratories would accept samples delivered by pneumatic tube (14 with a comment) and 21 laboratories would not accept them.
Sixty-nine laboratories had guidelines recommending sampling at least12 h post event, a few said samples should be taken within one week of an event and not after two weeks. Fourteen laboratories would not accept samples taken outside the time guidelines (5 if the sample was taken too soon).
In response to a question 'What are your sample rejection policies?' the following reasons were given and are listed in Table 1 .
Most laboratories asked for a simultaneous blood sample. This was used to measure a combination of bilirubin, protein or glucose or all three.
The average number of samples received per year was 131 per hospital but some hospitals received o5.
If there was a problem with the sample nine hospitals would ask for a repeat but most would qualify the request.
When asked about the spectrophotometric analysis of CSF, 54 laboratories had an SOP for the analysis, two did not. Everyone quoted relevant references for the method and more than half o¡ered the analysis 24/7. All laboratories o¡ered interpretation and most had an SOP for this. Chemical pathologists or clinical scientists mainly interpreted scans but also a signi¢-cant number of biomedical scientists.
An absorbance unit (AU) of 0.1 was the most popular full-scale de£ection scale used as recommended by guidelines 1 and p0.007 was used by all but one laboratory as the signi¢cant cut-o¡ value. Almost everyone used 476 nm as the wavelength for measuring the net bilirubin absorbance but seven laboratories gave other wavelengths ranging from 454 to 475 nm.
When asked to comment on the result of a scan with oxyhaemoglobin of 0.09 AU and no signi¢cant bilirubin almost everyone would use the appropriate phrase from the guidelines or something similar.
Scans were retained for a year or more by almost everyone and most laboratories had their spectrophotometer serviced regularly but a few did not have checks on absorption and wavelengths performed.
Discussion
Eighty-four laboratories in the UK returned the questionnaire. Unfortunately we do not know the number of laboratories analysing CSF who did not respond. There may be some who do not have contact with their regional audit committees and were therefore not audited by this procedure. Also some laboratories may have not responded to the questionnaire for various reasons such as not having time to do so or not o¡ering any measurements for CSF. At the end of 2004 around 220 laboratories in the UK were sending returns on analysis of protein and glucose to UK NEQAS and 110 laboratories were regularly returning results of analysis of haem pigments. Thus about 34% of laboratories in UK NEQAS measuring CSF glucose responded to the questionnaire and 48% of those analysing haem pigments.
Protein and glucose were analysed by almost all respondents and lactate by about one-third but there was little consensus for the reference ranges reported. Reference ranges may be based on manufacturer's recommendations, literature or derived by the laboratory. Di¡erent manufacturers' reagents may give di¡er-ent results and so di¡erent reference ranges may be appropriate. This has been seen for protein samples measured using pyrogallol red reagents in quality assurance schemes. For example the Olympus method gives consistently higher results than the Beckman method. Reference ranges reported in the literature are often based on methods that are no longer in common use and, although it may be a di⁄cult exercise, ranges should be based on current methodology.
Many laboratories quoted age-related reference ranges for CSF protein in children but none for adults even though concentrations of protein rise with increasing adult age. 2 Preparation of local reference ranges should take this into account.
A 60% of serum glucose was the most commonly quoted, but of course this would always entail a serum glucose measurement being done at the same time of CSF sampling. The use of a percentage rather than a reference range is more appropriate if the glucose measurement is being used to aid the diagnosis of bacterial infection and a value below 40% may be more appropriate. 3 The number of laboratories o¡ering CSF lactate measurement is surprisingly few (30% of respondents, 60% of participants in UK NEQAS) considering that lactate is now relatively easy to measure on most automated analytical platforms. There is evidence that in suspected cases of meningitis a CSF lactate above a cut-o¡ concentration of 4.2 mmol/L suggests bacterial aetiology and is a superior test to glucose in distinguishing between bacterial and viral meningitis. The results of the questionnaire showed that the majority of laboratories are performing spectrophotometric analysis of CSF in a satisfactory manner.
However there are a few concerns that this questionnaire has highlighted.
(1) There were six hospitals not o¡ering spectrophotometric scanning of CSF. This number may be an underestimate as we do not know how many hospitals did not answer the questionnaire because they too do not o¡er this test. There are about 250 laboratories in the UK NEQAS scheme for CSF biochemistry, about 120 of which return results of spectrophotometric scans so over half of those laboratories o¡ering scans did not respond to the questionnaire for some reason. Some hospitals may not o¡er spectrophotometric scanning of the CSF because there is no demand for the test from clinicians looking after patients with suspected SAH despite the risk of catastrophic misdiagnosis. 4 (2) We would advise that a spectrophotometric scan be performed no matter what the result of visual inspection for a numerical record of the net bilirubin absorption and experience is gained of the spectrophotometric appearance of obviously positive samples. (3) We were concerned about the rejection of samples for spectrophotometric analysis if they were not collected or delivered to the laboratory in a correct manner. These samples are unrepeatable and we feel that they should always be analysed. Comments can be made with the results about the possible e¡ects of mistreatment.
(4) Interpretation of results from repeat samples of CSF can be di⁄cult because of the possible introduction of blood into the CSF from an earlier sampling procedure. (5) Some laboratories are not using 476 nm to measure net bilirubin absorption even though this is clearly stated in national published guidance. 1 Laboratories should look at the way they are analysing CSF and check that they are conforming to best practice. Consensus reference ranges and cut-o¡s for CSF protein, glucose and lactate should be achievable.
Please give any further information that you feel is of relevance, including copies of any SOPs if desired.
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